KPF
XFOR icon

K2 Principal Fund’s X4 Pharmaceuticals XFOR Stock Holding History

K2 Principal Fund’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,972
Closed -$59.7K – 359
2024
Q3 		$59.7K Sell
2,972
-13,333
-82% -$278K 0.01% 217
2024
Q2 		$284K Buy
+16,305
New +$533K 0.05% 159

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

K2 Principal Fund's XFOR Position: Q4 2024 in Review

K2 Principal Fund sold out of X4 Pharmaceuticals (XFOR) in Q4 2024, closing a stake of 2,972 shares — an estimated $59.7K sold.

K2 Principal Fund first reported a position in XFOR in Q2 2024 and held it in 2 quarters. The position peaked at $284K in Q2 2024. 89 funds tracked by Wall St. Rank hold XFOR as of Q4 2024.

  • K2 Principal Fund reported no remaining X4 Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • K2 Principal Fund sold 2,972 X4 Pharmaceuticals shares in Q4 2024, an estimated $59.7K.
  • K2 Principal Fund first reported a position in X4 Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • K2 Principal Fund's X4 Pharmaceuticals position peaked at $284K in Q2 2024.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2024.

Based on K2 Principal Fund's 13F filing for Q4 2024, filed 14 Feb 2025.